BioMarin Submits Kuvan For Phenylketonuria
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm is asking FDA for a priority review, which would potentially allow for a late 2007 launch of the orphan drug.
You may also be interested in...
FDA Clears First Drug To Treat Phenylketonuria
BioMarin estimates Kuvan revenue of $57,000 per patient per year.
FDA Clears First Drug To Treat Phenylketonuria
BioMarin estimates Kuvan revenue of $57,000 per patient per year.
BioMarin Licenses UCSF Technology To Address Cause of Cystic Fibrosis
UCSF researcher Alan Verkman will have an ongoing role in lead optimization and development, BioMarin’s CEO tells “The Pink Sheet” DAILY.